For patients with PI3K mutated metastatic breast cancer who progress on a PI3K inhibitor, will you use an alternative PI3K inhibitor subsequently?

Would you consider using an alternative PI3K inhibitor as a subsequent treatment in patients with PI3K-mutated metastatic breast cancer who have progressed on a PI3K inhibitor?

• Yes, as immediate next line
• Yes, but only with an alternating class of drug in between
• No, I prefer alternate therapy due to concern for potential resistance
• Possibly, depending on initial PI3K response, and degree of progression
• Other